Details for New Drug Application (NDA): 019152
✉ Email this page to a colleague
NDA 019152 describes CALAN SR, which is a drug marketed by Pfizer and is included in one NDA. Additional details are available on the CALAN SR profile page.
The generic ingredient in CALAN SR is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
The generic ingredient in CALAN SR is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Summary for 019152
| Tradename: | CALAN SR |
| Applicant: | Pfizer |
| Ingredient: | verapamil hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 019152
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 16, 1986 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 180MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 15, 1989 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Mar 6, 1991 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
